Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Development of an orthosis for walking assistance using pneumatic artificial muscle: a quantitative assessment of the effect of assistance.

Kawamura T, Takanaka K, Nakamura T, Osumi H.

IEEE Int Conf Rehabil Robot. 2013 Jun;2013:6650350. doi: 10.1109/ICORR.2013.6650350.

PMID:
24187169
2.

Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling.

Sakurai H, Kubota K, Inaba S, Takanaka K, Shinagawa A.

Mol Cell Proteomics. 2013 Aug;12(8):2313-23. doi: 10.1074/mcp.M112.023853. Epub 2013 May 14.

3.

Odd-numbered perfluorocarboxylates predominate over perfluorooctanoic acid in serum samples from Japan, Korea and Vietnam.

Harada KH, Hitomi T, Niisoe T, Takanaka K, Kamiyama S, Watanabe T, Moon CS, Yang HR, Hung NN, Koizumi A.

Environ Int. 2011 Oct;37(7):1183-9. doi: 10.1016/j.envint.2011.04.011. Epub 2011 May 19.

PMID:
21600654
4.
5.

Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.

Mizushima H, Takanaka K, Abe K, Fukazawa I, Ishizuka H.

Xenobiotica. 2007 Jan;37(1):59-73.

PMID:
17178634
6.

Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population.

Iwasaki M, Yoshimura Y, Asahi S, Saito K, Sakai S, Morita S, Takenaka O, Inoda T, Kashiyama E, Aoyama A, Nakabayashi T, Omori S, Kuwabara T, Izumi T, Nakamura K, Takanaka K, Nakayama Y, Takeuchi M, Nakamura H, Kametani S, Terauchi Y, Hashizume T, Nagayama S, Kume T, Achira M, Kawai H, Kawashiro T, Nakamura A, Nakai Y, Kagayama A, Shiraga T, Niwa T, Yoshimura T, Morita J, Ohsawa F, Tani M, Osawa N, Ida K, Noguchi K.

Drug Metab Pharmacokinet. 2004 Dec;19(6):444-52.

7.

Sesquiterpene glucosides from anti-leukotriene B4 release fraction of Taraxacum officinale.

Kashiwada Y, Takanaka K, Tsukada H, Miwa Y, Taga T, Tanaka S, Ikeshiro Y.

J Asian Nat Prod Res. 2001;3(3):191-7.

PMID:
11491394
8.

cDNA cloning of mutant catalase in acatalasemic beagle dog: single nucleotide substitution leading to thermal-instability and enhanced proteolysis of mutant enzyme.

Nakamura K, Watanabe M, Takanaka K, Sasaki Y, Ikeda T.

Int J Biochem Cell Biol. 2000 Nov-Dec;32(11-12):1183-93.

PMID:
11137458
9.

Anisotropy of upper critical field and pairing symmetry.

Takanaka K, Kuboya K.

Phys Rev Lett. 1995 Jul 10;75(2):323-325. No abstract available.

PMID:
10059665
10.

Comment on "Angle dependence of the upper critical field of superconducting superlattices"

Iwai T, Miyake S, Takanaka K.

Phys Rev B Condens Matter. 1995 May 1;51(17):12013. No abstract available.

PMID:
9977960
11.

Effects of beta-adrenergic agonists on metabolic activations of human neutrophils.

Taniguchi K, Masuda Y, Takanaka K.

J Pharmacobiodyn. 1991 Aug;14(8):435-42.

PMID:
1685514
12.

Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils.

Taniguchi K, Masuda Y, Takanaka K.

J Pharmacobiodyn. 1991 Feb;14(2):87-93.

PMID:
1678430
13.

Reversible drug effects on the metabolic activation of polymorphonuclear leukocytes.

Takanaka K, Taniguchi K, Masuda Y, O'Brien PJ.

Chem Biol Interact. 1990;73(2-3):309-21.

PMID:
2155714
14.

Action sites of antiallergic drugs on human neutrophils.

Taniguchi K, Masuda Y, Takanaka K.

Jpn J Pharmacol. 1990 Jan;52(1):101-8.

15.

Inhibitions of metabolic responses of polymorphonuclear leukocytes by antiallergic drugs.

Taniguchi K, Takanaka K.

J Pharmacobiodyn. 1989 Jan;12(1):37-42.

PMID:
2542518
16.
17.
18.

[Effects of antiallergic agents on polymorphonuclear leukocytes. The inhibition of arachidonic acid release and superoxide production].

Taniguchi K, Urakami M, Takanaka K.

Nihon Yakurigaku Zasshi. 1987 Aug;90(2):97-103. Japanese.

PMID:
2890562
19.

[Use of an LED device for the adjustment of articulators].

Itakura Y, Takanaka K, Ohtomo T, Hobo S, Uruta K.

Tohoku Shika Daigaku Gakkai Shi. 1986 Mar;13(1):12-22. Japanese. No abstract available.

PMID:
3462100
20.
22.

Tumor promoter stimulated irreversible binding of N-methylaminoazobenzene to polymorphonuclear leukocyte DNA.

Takanaka K, O'Brien PJ, Tsuruta Y, Rahimtula AD.

Cancer Lett. 1982 Mar-Apr;15(3):311-5. No abstract available.

PMID:
7116333
23.

Generation of activated oxygen species by polymorphonuclear leukocytes.

Takanaka K, O'Brien PJ.

FEBS Lett. 1980 Feb 11;110(2):283-6. No abstract available.

24.
25.

NAD(P)H oxidase levels of intact leukocytes of CGD (chronic granulomatous disease).

Takanaka K, Usui T, O'Brien J.

Hiroshima J Med Sci. 1977 Dec;26(4):321-4. No abstract available.

PMID:
615179
26.

Mechanisms of H2O2 formation by leukocytes. Evidence for a plasma membrane location.

Takanaka K, O'Brien PJ.

Arch Biochem Biophys. 1975 Aug;169(2):428-35. No abstract available.

PMID:
1180558
27.

Mechanisms of H2O2 formation by leukocytes. Properties of the NAD(P)H oxidase activity of intact leukocytes.

Takanaka K, O'Brien PJ.

Arch Biochem Biophys. 1975 Aug;169(2):436-42. No abstract available.

PMID:
170862
28.

Mechanisms of hydrogen peroxide formation in leukocytes: the NAD(P)H oxidase activity of myeloperoxidase.

Takanaka K, O'Brien PJ.

Biochem Biophys Res Commun. 1975 Feb 17;62(4):966-71. No abstract available.

PMID:
235265

Supplemental Content

Loading ...
Support Center